Table 1 Comparison of the age and gender distribution between patients and controls and the RA-related features of the patients
| Â | RA patients group | Control group | p |
|---|---|---|---|
Age (years) | 41.7 ± 13.8 | 43.8 ± 12.6 | 0.262 |
Gender (n, %) | |||
 Females | 81, 81.0% | 78, 78.0% |  |
Males | 19, 19% | 22, 22% | 0.599 |
 Duration of RA (years) | 10.2 ± 4.7 |  |  |
 Duration of morning stiffness (min) | 62.6 ± 30.4 |  |  |
 SJC | 11.5 ± 4.9 |  |  |
(range, 4-21) | Â | Â | |
 TJC | 11.0 ± 5.4 |  |  |
(range, 3-22) | Â | Â | |
 VAS-pain score | 47.8 ± 23.4 |  |  |
(range, 13-81) | Â | Â | |
 DAS28-ESR | 4.1 ± 0.9 |  |  |
(range, 2.1-6.6) | Â | Â | |
Activity status based on DAS28-ESR (n, %) | |||
 Remission | 7, 7.0% |  |  |
 Low disease activity | 14, 14.0% |  |  |
 Moderate disease activity | 66, 66.0% |  |  |
 High disease activity | 13, 13.0% |  |  |
Drug intake (n, %) | |||
 Glucocorticoids | 21, 21.0% |  |  |
 Methotrexate | 46, 46.0% |  |  |
 Leflunomide | 34, 34.0% |  |  |
 Hydroxychloroquine | 64, 64.0% |  |  |
 Biological | 21, 21.0% |  |  |
ESR (mm/h) | 64.2 ± 28.9 |  |  |
CRP (mg/dl) | 39.4 ± 18.7 |  |  |
RF titer (U/ml) | 39.9 ± 16.9 |  |  |
Anti-CCP titer (IU/ml) | 30.3 ± 12.2 |  |  |
Modified Sharp score | 27.4 ± 6.4 |  |  |